Areas of interest at Schwarz Pharma
Schwarz Pharma business development
SCHWARZ PHARMA AG is a member of UCB group, which
- develops and markets innovative drugs with the focus on Central Nervous System (CNS) as well as cardiovascular and gastro-intestinal diseases
- employs around 3,900 professionals worldwide
- operates state of the art manufacturing facilities in Europe, USA and Asia
- has a strong multinational marketing presence and infrastructure with affiliates in the USA, Europe and Asia
- is headquartered in Monheim, Germany.
In 2006 the company achieved global sales of EUR 1 bln, of which 79% were generated outside Germany. The company focusses on search and development in the therapeutic areas of the Central Nervous System (CNS). It has a substantial late stage pipeline with development projects for the treatment of Parkinson's disease, Restless Legs Syndrome, epilepsy and neuropathic pain. The Parkinson´s patch Neupro® (rotigotine transdermal system) is the first project from clinical development that has been launched.
UCB (Brussels, Belgium) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative products in the fields of
- central nervous system disorders
- allergy/respiratory diseases
- immune and inflammation disorders and
SCHWARZ PHARMA prefers innovative project opportunities at clinical stage and offers strong clinical and regulatory capabilities, proven marketing support and expertise in managing multinational development alliances. Beside in-licensing and selective basic research, the company is also exploring new CNS indications with existing compounds.
Partnership is a key factor in the development strategy at SCHWARZ PHARMA. Nearly all of their projects involve cooperation with other companies and they are very experienced at developing strong relationships with our partners in order to ensure the success of the project and our mutual success.
In most cases, their development team is multinational in structure, using expertise from their development groups in Germany and the US. Together with theri partner, they form a project team which coordinates all the development activities and uses specialist expertise from external consultants, when necessary.
They also like to form strong relationships with academic centers of excellence so that they can support basic research and also provide opportunities to apply that research, when appropriate. Through such relationships they are often able to provide training or employment opportunities for young scientists. Schools of pharmacy, chemistry, biochemistry, pharmacology and many other scientific disciplines can form mutually rewarding and satisfying partnerships with SCHWARZ PHARMA.